BR112013007696A2 - compound, pharmaceutical composition, uses of said compound and said composition - Google Patents

compound, pharmaceutical composition, uses of said compound and said composition

Info

Publication number
BR112013007696A2
BR112013007696A2 BR112013007696A BR112013007696A BR112013007696A2 BR 112013007696 A2 BR112013007696 A2 BR 112013007696A2 BR 112013007696 A BR112013007696 A BR 112013007696A BR 112013007696 A BR112013007696 A BR 112013007696A BR 112013007696 A2 BR112013007696 A2 BR 112013007696A2
Authority
BR
Brazil
Prior art keywords
compound
composition
uses
pharmaceutical composition
virus
Prior art date
Application number
BR112013007696A
Other languages
Portuguese (pt)
Inventor
B Shankar Bandarpalle
Hu Bin
Zhong Bin
J Lavey Brian
Shen Changmao
A Coburn Craig
Yang De-Yi
Sun Frei
Nair Anilkumar G
Zhou Guowei
Wu Hao
A Kozlowski Joseph
M Keertikar Kartik
Chen Lei
Tong Ling
P Dwyer Michael
Wong Michael
B Selyutin Oleg
Zeng Qingbei
Rizvi Razia
B Rosenblum Stuart
Ji Tao
Yu Wensheng
Jiang Yueheng
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PCT/CN2010/077493 priority Critical patent/WO2012040923A1/en
Priority to US201061426724P priority
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Priority to PCT/CN2011/001638 priority patent/WO2012041014A1/en
Publication of BR112013007696A2 publication Critical patent/BR112013007696A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Abstract

compound, pharmaceutical composition, uses of said compound and said composition. are provided tetracyclic indole derivatives of formula (1), are pharmaceutically acceptable thereof and their pharmaceutical compositions, wherein a, a, a, a, a, a, v. w, w, x, x <39>, y, y <39> are as defined in the invention. Use of these derivatives to treat hepatitis c virus (hepatitis c virus, hcv) infection is also provided.
BR112013007696A 2010-09-29 2011-09-28 compound, pharmaceutical composition, uses of said compound and said composition BR112013007696A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/CN2010/077493 WO2012040923A1 (en) 2010-09-29 2010-09-29 Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
US201061426724P true 2010-12-23 2010-12-23
PCT/CN2011/001638 WO2012041014A1 (en) 2010-09-29 2011-09-28 Tetracyclic indole derivatives for treating hepatitis c virus infection

Publications (1)

Publication Number Publication Date
BR112013007696A2 true BR112013007696A2 (en) 2019-09-24

Family

ID=45891857

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013007696A BR112013007696A2 (en) 2010-09-29 2011-09-28 compound, pharmaceutical composition, uses of said compound and said composition

Country Status (8)

Country Link
EP (1) EP2621931A4 (en)
JP (1) JP2013538831A (en)
KR (1) KR20140001879A (en)
AU (1) AU2011307953B2 (en)
BR (1) BR112013007696A2 (en)
CA (1) CA2811662A1 (en)
MX (1) MX2013003631A (en)
WO (1) WO2012041014A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2430014E (en) 2009-05-13 2015-10-20 Gilead Pharmasset Llc Antiviral compounds
AR077060A1 (en) 2009-06-11 2011-07-27 Abbott Lab antiviral compounds
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
CA2767887A1 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
JP2013522375A (en) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Analogs for treating or preventing flavivirus infection
WO2012027712A2 (en) 2010-08-26 2012-03-01 Emory University Potent and selective inhibitors of hepatitis c virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
BR112014000563A2 (en) 2011-07-09 2017-06-13 Sunshine Lake Pharma Co Ltd compound, pharmaceutical composition, and compound use
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
ES2659216T3 (en) 2011-09-16 2018-03-14 Gilead Pharmasset Llc Methods for the treatment of HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2862755A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
TWI610916B (en) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceuticals applications thereof
CN103848821B (en) 2012-11-29 2016-10-12 广东东阳光药业有限公司 Spiro-compound, pharmaceutical composition and their purposes as hepatitis c inhibitor
CN103848818B (en) 2012-11-29 2017-03-15 广东东阳光药业有限公司 Simultaneously cycle compound, pharmaceutical composition and their applications in medicine as hepatitis c inhibitor
WO2014110687A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2014110688A1 (en) * 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiophene- sub stitued tetracyclic compounds and methods of use thereof for the treatment of viral diseases
UA118256C2 (en) 2013-01-31 2018-12-26 Гіліад Фармассет Елелсі Combination formulation of two antiviral compounds
WO2014121418A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
CN104230946B (en) * 2013-06-06 2017-03-08 爱博新药研发(上海)有限公司 The compound of suppression hepatitis C virus, pharmaceutical composition and its application
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3063145A4 (en) * 2013-10-30 2017-08-23 Merck Sharp & Dohme Corp. Process for preparing tetracyclic heterocycle compounds
WO2015089810A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104803989B (en) 2014-01-23 2017-12-22 广东东阳光药业有限公司 Application as the endocyclic compound of hepatitis c inhibitor and its in medicine
WO2016004899A1 (en) * 2014-07-11 2016-01-14 Merck Sharp & Dohme Corp. Process for making tetracyclic heterocycle compounds
WO2016196932A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Process for preparing substituted tetracyclic heterocycle compounds
WO2017181947A1 (en) * 2016-04-20 2017-10-26 深圳市塔吉瑞生物医药有限公司 Substituted diamine carbamate, and pharmaceutical composition and application thereof
WO2018032468A1 (en) * 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
WO2018032467A1 (en) * 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
RU2650610C1 (en) 2017-02-28 2018-04-16 Васильевич Иващенко Александр Antiviral composition and method of its application
RU2659388C1 (en) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Nucleotides including n-[(s)-1-cyclobutoxycarbonyl]phosphoramidate fragment, their analogs and their application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7745636B2 (en) * 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2682393A1 (en) * 2008-12-03 2014-01-08 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A comprising a bicyclic core.
CA2750577A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
CN102427729B (en) * 2009-03-27 2014-09-03 默沙东公司 Inhibitors of hepatitis C virus replication

Also Published As

Publication number Publication date
AU2011307953A1 (en) 2013-04-04
EP2621931A4 (en) 2014-03-19
AU2011307953B2 (en) 2014-07-31
MX2013003631A (en) 2013-10-01
EP2621931A1 (en) 2013-08-07
CA2811662A1 (en) 2012-04-05
KR20140001879A (en) 2014-01-07
WO2012041014A1 (en) 2012-04-05
JP2013538831A (en) 2013-10-17

Similar Documents

Publication Publication Date Title
JO2593B1 (en) HCV NS3 Protease Inhibitors
CA2753382C (en) Hepatitis c virus inhibitors
DK2097434T3 (en) Nucleosidaryl phosphoramidates and their use as antivirals for the treatment of hepatitis C virus
CY1112999T1 (en) INHIBITORS VIRUS HEPATITIS c
BR112014000371A2 (en) trifluoromethyl oxadiazole derivatives and their use in the treatment of disease
NZ576817A (en) Hepatitis c virus inhibitors
UA96975C2 (en) Compounds, pharmaceutical compositions for the treatment of virus infections
TW200720285A (en) Nucleoside compounds for treating viral infections
SG178952A1 (en) Chemical compounds
MX2010006209A (en) Quinoxalinyl derivatives.
WO2010118367A3 (en) Antiviral pyrimidines
BR112015014457A2 (en) pharmaceutically acceptable salt or compound thereof and pharmaceutical composition and its uses and processes for improving or treating hcv infection, for inhibiting hepatitis c virus ns5b polymerase activity and hepatitis c virus replication
BRPI0517343A (en) betulin derivatives, their preparation and their use
MX344879B (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
MX2009004556A (en) Hcv ns3 protease inhibitors.
EA201170241A1 (en) Macrocyclic khinoxaline compounds as hcv protease inhibitors ns3 inhibitors
NZ596579A (en) Bace inhibitors
MX2007003538A (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection.
BRPI0613962A2 (en) innovative macrocyclic hepatitis c virus replication inhibitors
EA200802346A1 (en) Cyclopropilcondenated indobobenzezepinova inhibitors of helpatitis virus ns5b protein
BRPI1013394A2 (en) &#34;compound, pharmaceutical composition, use of the compound, and method for treating a hepatitis c virus infected patient.&#34;
UA116616C2 (en) Inhibitors hcv serine protease derived from macrocyclic proline
BR112012017269A2 (en) tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2015015692A (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection.
CO6561788A2 (en) Inhibitors the Hepatitis C virus

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law